ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
14-3-3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
background14-3-3γ is implicated in neurodegeneration, yet its role in postoperative cognitive dysfunction (POCD) remains unclear.
methodsWe performed CSF proteomic profiling using the SomaScan 7K platform in the Alzheimer's Disease Neuroimaging Initiative cohort (n = 237) to identify biomarkers associated with neurodegeneration-enriched cognitive vulnerability (NECV). A prospective surgical cohort (n = 213) was used to evaluate circulating 14-3-3γ levels in relation to perioperative cognitive outcomes. Mechanistic studies were conducted using a murine surgery model, AAV-mediated gene manipulation, neuronal cultures, pharmacological intervention, and molecular dynamics simulations.
resultsCSF proteomics identified 14-3-3γ as a candidate biomarker associated with NECV and neurodegenerative progression. Plasma 14-3-3γ levels were associated with POCD and postoperative delirium. In mice, anesthesia and surgery reduced hippocampal 14-3-3γ expression, accompanied by increased Tau phosphorylation at Thr205 among examined sites, synaptic dysfunction, and cognitive impairment. Neuronal 14-3-3γ overexpression rescued these deficits. Mechanistically, 14-3-3γ interacted with Tau in a phosphorylation-dependent manner and regulated Tau phosphorylation homeostasis. Pharmacological stabilization of the 14-3-3γ-Tau interaction using FC-A reduced Tau Thr205 phosphorylation and improved cognition, whereas TauT205E expression diminished this rescue effect.
conclusions14-3-3γ represents a potential regulator of postoperative cognitive vulnerability and a candidate therapeutic target for POCD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.